Newer treatments for fibromyalgia syndrome by Harris, Richard E & Clauw, Daniel J
© 2008 Dove Medical Press Limited.   All rights reserved
Therapeutics and Clinical Risk Management 2008:4(6) 1331–1342 1331
REVIEW
Newer treatments for ﬁ  bromyalgia syndrome
Richard E Harris
Daniel J Clauw
Department of Anesthesiology, 
The University of Michigan, Ann 
Arbor, MI, USA
Correspondence: Richard E Harris
Chronic Pain and Fatigue Research 
Center, 24 Frank Lloyd Wright Drive, 
PO Box 385, Lobby M, Ann Arbor, 
MI 48106, USA
Tel +1 734 998 6996
Fax +1 734 998 6900
Email reharris@med.umich.edu
Abstract: Fibromyalgia syndrome is a common chronic pain disorder of unknown etiology. The 
lack of understanding of the pathophysiology of ﬁ  bromyalgia has made this condition frustrating 
for patients and clinicians alike. The most common symptoms of this disorder are chronic 
widespread pain, fatigue, sleep disturbances, difﬁ  culty with memory, and morning stiffness. 
Emerging evidence points towards augmented pain processing within the central nervous 
system (CNS) as having a primary role in the pathophysiology of this disorder. Currently the 
two drugs that are approved by the United States Food and Drug Administration (FDA) for the 
management of ﬁ  bromyalgia are pregabalin and duloxetine. Newer data suggests that milnacipran, 
a dual norepinephrine and serotonin reuptake inhibitor, may be promising for the treatment 
of ﬁ  bromyalgia. A double-blind, placebo-controlled trial of milnacipran in 125 ﬁ  bromyalgia 
patients showed signiﬁ  cant improvements relative to placebo. Milnacipran given either once 
or twice daily at doses up to 200 mg/day was generally well tolerated and yielded signiﬁ  cant 
improvements relative to placebo on measures of pain, patient’s global impression of change 
in their disease state, physical function, and fatigue. Future studies are needed to validate the 
efﬁ  cacy of milnacipran in ﬁ  bromyalgia.
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Fibromyalgia in the context of other central pain 
syndromes
Clinical practitioners commonly see patients with pain and other somatic symptoms 
that they cannot adequately explain based on the degree of damage or inﬂ  ammation 
noted in peripheral tissues. In fact, pain may be amongst the most common ailments 
that individuals seek medical attention for (Khan et al 2003). Typically, an evaluation 
is performed looking for a “cause” for the pain. If none is found, these individuals are 
often given a diagnostic label that merely connotes that the patient has chronic pain in 
a region of the body, without an underlying mechanistic cause (eg, chronic low back 
pain, headache, temporomandibular disorder [TMD], etc). In other cases, the label 
given alludes to an underlying mechanism that may or may not be responsible for the 
individual’s pain (eg, facet syndrome).
Fibromyalgia is merely the current term for individuals with chronic widespread 
musculoskeletal pain, for which no alternative cause can be identiﬁ  ed. Gastroenterologists 
often see the exact same patients and focus on their gastroenterological complaints, 
and often use the terms functional GI disorder, irritable bowel syndrome (IBS), 
nonulcer dyspepsia, or esophageal dysmotility to explain the patient’s symptoms 
(Mayer and Raybould 1990). Neurologists see these patients for their headaches 
and/or unexplained facial pain, urologists for pelvic pain and urinary symptoms 
(and use labels such as interstitial cystitis, chronic prostatitis, vulvodynia, and vulvar 
vestibulitis), dentists for TMD, and so on. These syndromes may have a common 
underlying pathology.Therapeutics and Clinical Risk Management 2008:4(6) 1332
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Until recently these unexplained pain syndromes 
perplexed researchers, clinicians, and patients. However, it 
is now clear that:
•  Individuals will sometimes only have one of these 
“idiopathic” pain syndromes over the course of their 
lifetime. But more often, individuals with one of these 
entities, and their family members, are likely to have 
several of these conditions (Hudson et al 1985; Arnold 
et al 2004a). Many terms have been used to describe these 
clustering syndromes and symptoms, including functional 
somatic syndromes, somatization disorders, allied spectrum 
conditions, chronic multisymptom illnesses, medically 
unexplained symptoms, etc (Hudson et al 1985; Fukuda 
et al 1998; Barsky and Borus 1999; Wessely et al 1999).
•  Women are more likely to have these disorders than men, 
but the sex difference is much more apparent in clinical 
samples than in population-based samples (Drossman 
et al 1993; Aaron et al 1996).
•  Groups of individuals with these conditions (eg, 
ﬁ  bromyalgia, IBS, headache, TMD, etc) display diffuse 
hyperalgesia (increased pain to normally painful stimuli) 
and/or allodynia (pain to normally nonpainful stimuli) 
(Maixner et al 1995; Naliboff et al 2001; Giesecke et al 
2004a, 2004b; Moshiree et al 2007). This suggests that 
these individuals have a fundamental problem with pain 
or sensory processing rather than an abnormality conﬁ  ned 
to the region of the body where the person is currently 
experiencing pain.
•  Similar types of therapies are efﬁ  cacious for all of these 
conditions, including both pharmacological (eg, tricyclic 
compounds such as amitriptyline) and nonpharmacological 
treatments (eg, exercise, cognitive behavioral therapy). 
Conversely, individuals with these conditions typically 
do not respond to therapies that are effective when pain is 
due to damage or inﬂ  ammation of tissues (eg, nonsteroidal 
anti-inﬂ  ammatory drugs [NSAIDs], opioids, injections, 
surgical procedures).
Until perhaps a decade ago, these conditions were all on 
somewhat equally tenuous scientiﬁ  c grounds. But within 
a relatively short period of time, research methods such as 
experimental pain testing, functional imaging, and genetics 
have led to tremendous advances in the understanding of 
several of these conditions, most notably ﬁ  bromyalgia, IBS, 
and TMD. Many in the pain ﬁ  eld now feel that chronic pain 
itself is a “disease” and that many of the underlying mecha-
nisms operative in these heretofore-considered “idiopathic” or 
“functional” pain syndromes may be similar no matter whether 
that pain is present throughout the body (eg, in ﬁ  bromyalgia) 
or localized to the low back, the bowel, or the bladder. Because 
of this, the more contemporary terms used to describe con-
ditions such as ﬁ  bromyalgia, IBS, TMD, vulvodynia, and 
many other entities include “central pain” “neuropathic pain” 
(meaning that the pain is coming from the nervous system 
rather than the periphery and not pain due to nerve damage), 
or “nonnociceptive pain” (Clauw 2007; Woolf 2004).
This review of ﬁ  bromyalgia focuses on our current under-
standing of this disorder and its treatment with pharmacologic 
interventions.
Historical perspective
Although the term “ﬁ  bromyalgia” is relatively new, this condi-
tion has been described in the medical literature for centuries. 
Sir William Gowers coined the term ‘ﬁ  brositis’ in 1904. During 
the next half century, ﬁ  brositis was considered by some to be 
a common cause of muscular pain, by others to be a manifes-
tation of ‘tension’ or ‘psychogenic rheumatism’, and by the 
rheumatology community in general to be a non-entity. The 
current concept of ﬁ  bromyalgia was established by Smythe and 
Moldofsky in the mid-1970s (1977). The name change reﬂ  ected 
the fact that there was increasing evidence that there was no –itis 
or inﬂ  ammation in the connective tissues of individuals with 
this condition, but instead –algia or pain. These authors char-
acterized the most common tender points or regions of extreme 
tenderness in these individuals, and reported that patients with 
ﬁ  bromyalgia had disturbances in deep and restorative sleep, 
and that selective stage 4 interruptions induced the symptoms 
of ﬁ  bromyalgia (Moldofsky et al 1975). Yunus and colleagues 
(1981) then reported on the major clinical manifestations of 
patients with ﬁ  bromyalgia seen in rheumatology clinics.
The next advance in ﬁ  bromyalgia was the development 
of the American College of Rheumatology (ACR) criteria 
for ﬁ  bromyalgia, which were published in 1990 (Wolfe et al 
1990). These classiﬁ  cation criteria require that an individual 
have both a history of chronic widespread pain (CWP), 
and the ﬁ  nding of 11 of a possible 18 tender points on 
examination. These ACR classiﬁ  cation criteria were intended 
for research use, to standardize deﬁ  nitions of ﬁ  bromyalgia. 
In this regard, the criteria have been extremely valuable. 
Unfortunately, many practitioners use these criteria in routine 
clinical practice to diagnose individual patients, and this 
unintended use has led to many of the current misconceptions 
regarding ﬁ  bromyalgia, that are discussed below.
The ﬁ  nding of diffusely increased tenderness, as well as 
a lack of ﬁ  nding “–itis” in the muscles or other tissues of 
ﬁ  bromyalgia patients, caused the name of this entity to be 
changed from ﬁ  brositis to ﬁ  bromyalgia. The diffuse nature of Therapeutics and Clinical Risk Management 2008:4(6) 1333
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the pain and tenderness also led many groups of investigators 
to begin to explore neural mechanisms to explain the underly-
ing pathogenesis of these disorders (Yunus 1992; Clauw and 
Chrousos 1997). In fact, major advances have only occurred 
in understanding individual syndromes within this spectrum 
once investigators concluded that this was not a condition 
caused by peripheral damage or inﬂ  ammation, and began to 
explore central, neural mechanisms of these diseases. Thus, 
the conditions we now understand best within this spectrum 
include ﬁ  bromyalgia, IBS, and TMD.
Epidemiology
Chronic widespread pain
Epidemiological studies of the historical component of the 
ACR criteria for ﬁ  bromyalgia have been extremely instructive. 
CWP is typically operationalized as pain above and below the 
waist, involving the left and right sides of the body, and also 
involving the axial skeleton. Population-based studies of CWP 
suggest that 5%–15% of the population has this symptom at 
any given point in time (Croft et al 1993; Wolfe et al 1995; 
Cöster et al 2007). Chronic regional pain is found in 20% to 
25% of the population. Both chronic widespread and regional 
pain occur about 1.5 times as commonly in women than men. 
Between 25% and 50% of individuals who have CWP will 
also have 11 or greater tender points, and thus meet criteria 
for ﬁ  bromyalgia (Jacobsen and Bredkjaer 1992; Cöster et al 
2007). The prevalence of ﬁ  bromyalgia is just as high in rural or 
nonindustrialized societies as it is in countries such as the US 
(Raspe 1992; White and Thompson 2003; Peleg et al 2007).
In summary, although many clinicians uniquely associate 
ﬁ  bromyalgia with women who display high levels of distress, 
much of this is an artifact of: 1) the ACR criteria that 
require 11 tender points, and 2) the fact that most studies 
of ﬁ  bromyalgia have originated from clinical samples from 
tertiary care centers, where healthcare seeking behaviors lead 
to the fact that psychological and psychiatric co-morbidities 
are much higher (Aaron et al 1996). When all these biases are 
eliminated by examining CWP in population-based studies, 
a clearer picture of ﬁ  bromyalgia is obtained, and chronic 
widespread pain becomes much like chronic musculoskeletal 
pain in any other region of the body.
Etiology
Genetic factors
Research has indicated a strong familial component to 
the development of ﬁ  bromyalgia. First degree relatives of 
individuals with ﬁ  bromyalgia display an eight-fold greater 
risk of developing ﬁ  bromyalgia than those in the general 
population (Arnold et al 2004a). These studies also show 
that family members of individuals with ﬁ  bromyalgia are 
much more tender than the family members of controls, 
regardless of whether they have pain or not. Family members 
of ﬁ  bromyalgia patients are also much more likely to have 
IBS, TMD, headaches, and a host of other regional pain 
syndromes (Hudson et al 1985; Buskila et al 1996; Kato 
et al 2006b). This familial and personal co-aggregation 
of conditions which includes ﬁ  bromyalgia was originally 
collectively termed affective spectrum disorder, (Hudson 
et al 1993) and more recently central sensitivity syndromes 
and chronic multisymptom illnesses (Fukuda et al 1998; 
Yunus 2008). In population-based studies, the key symptoms 
that often co-aggregate besides pain are fatigue, memory 
difﬁ  culties, and mood disturbances (Fukuda et al 1997, 
1998). Twin studies suggest that approximately half of the 
risk of developing CWP is due to genetic factors, and half 
environmental (Kato et al 2006a).
Recent studies have begun to identify speciﬁ  c genetic 
polymorphisms that are associated with a higher risk of 
developing ﬁ  bromyalgia. To date, the serotonin 5-HT2A 
receptor polymorphism T/T phenotype, serotonin transporter, 
dopamine 4 receptor, and COMT (catecholamine o-methyl 
transferase) polymorphisms have all been noted to be seen 
in higher frequency in ﬁ  bromyalgia (Bondy et al 1999; 
Offenbaecher et al 1999; Buskila et al 2004; Buskila 2007). 
It is of note that all of the polymorphisms identiﬁ  ed to 
date involve the metabolism or transport of monoamines, 
compounds that play a critical role in activity of the human 
stress response. However these trials have used a targeted 
approach where a speciﬁ  c gene polymorphism has been 
examined. It is likely that there are scores of other genetic 
polymorphisms, involving other neuromodulators as well as 
monoamines, which in part determine an individuals’ “set 
point” for pain and sensory processing.
Environmental factors
As with most illnesses that may have a genetic underpinning, 
environmental factors may play a prominent role in triggering 
the development of ﬁ  bromyalgia and related conditions. 
Environmental “stressors” temporally associated with 
the development of either ﬁ  bromyalgia or chronic fatigue 
syndrome includes physical trauma, certain infections such 
as Hepatitis C, Epstein Barr virus, parvovirus, Lyme disease, 
and emotional stress. The disorder is also associated with 
other regional pain conditions or autoimmune disorders 
(Buskila et al 1997; Clauw and Chrousos 1997; McLean 
and Clauw 2004). Of note, each of these stressors only Therapeutics and Clinical Risk Management 2008:4(6) 1334
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leads to CWP or ﬁ  bromyalgia in approximately 5%–10% of 
individuals who are exposed; the overwhelming majority of 
individuals who experience these same infections or other 
stressful events regain their baseline state of health.
An excellent recent example of how illnesses such as 
ﬁ  bromyalgia might be triggered occurred in the setting 
of the deployment of troops to liberate Kuwait during the 
Gulf War in 1990 and 1991. The term “Gulf War illnesses” 
is now commonly used to refer to a constellation of 
symptoms developed by some 10%–15% of the 7  00,000 
US troops deployed to the Persian Gulf in the early 1990s. 
The symptoms, which include headaches, muscle and joint 
pain, fatigue, memory disorders and gastrointestinal distress 
(Fukuda et al1998), were seen in troops deployed from the 
United Kingdom (UK) and other countries as well (Unwin 
et al 1999). The panels of experts who examined potential 
causes for these symptoms and syndromes found that the 
sickness could not be traced to any single environmental 
trigger, and noted the similarities between these individuals, 
and those diagnosed with ﬁ  bromyalgia and chronic fatigue. 
Furthermore, similar syndromes involving multiple somatic 
symptoms have been noted in veterans of every war the US 
or UK has been involved in during the past century (Hyams 
et al 1996). This suggests that war may be an environment 
where individuals are simultaneously exposed to a multitude 
of “stressors. triggering the development of this type of illness 
in susceptible individuals (Clauw 2003).
The above-noted relationship between individuals with 
other chronic rheumatic or autoimmune disorders deserves 
special attention, because of the relevance to practicing 
clinicians. As many as 25% of patients correctly diagnosed 
with generalized inﬂ  ammatory disorders such as systemic 
lupus erythmatosus (SLE), rheumatoid arthritis (RA), and 
ankylosing spondylitis will also fulﬁ  ll ACR criteria for 
ﬁ  bromyalgia (Clauw and Katz 1995). However, in clinical 
practice this co-expression may go unrecognized, especially 
when the fibromyalgia develops after the autoimmune 
disorder or regional pain syndrome. In this setting when 
co-morbid ﬁ  bromyalgia goes unrecognized, patients are 
often unnecessarily treated more aggressively with toxic 
immunosuppressive drugs.
Pathogenesis
Role of stressors
Once FIBROMYALGIA develops, the mechanisms 
responsible for ongoing symptom expression are likely 
complex and multifactorial. Because of the fact that disparate 
“stressors” can trigger the development of these conditions, 
the human stress response has been closely examined for 
a causative role. These systems are mediated primarily 
by the activity of the corticotropin-releasing hormone 
(CRH) nervous system located in the hypothalamus and 
locus–ceruleus–norepinephrine/autonomic (sympathetic/
LC-NE) nervous system in the brain stem. Recent research 
suggests that although this system in humans has been highly 
adaptive throughout history, the stress response may be 
inappropriately triggered by a wide assortment of everyday 
occurrences that do not pose a real threat to survival, 
thus initiating the cascade of physiologic responses more 
frequently than can be tolerated (Sapolsky 1996).
The type of stress and the environment in which it occurs 
also have an impact on how the stress response is expressed. An 
animal study has shown that that the strongest physiological 
responses are triggered by events that are accompanied by a 
lack of control or support, and thus viewed as perceived as 
inescapable or unavoidable (Chrousos and Gold 1992). In 
humans, daily “hassles” and personally relevant stressors 
seem to be more capable of causing symptoms, which may 
lead to ﬁ  bromyalgia, than major catastrophic events that do 
not personally impact on the individual (Pillow et al 1996).
Two studies performed in the US just before and after the 
terrorist attacks of 9/11 point out that not all psychological 
stress is capable of triggering or exacerbating ﬁ  bromyalgia 
or somatic symptoms. In one study performed by Raphael 
and colleagues (2002), no difference in pain complaints or 
other somatic symptoms was seen in residents of New York 
and New Jersey who had been surveyed prior to 9/11, and 
then just following the terrorist attacks on the World Trade 
Center. In another study performed in the Washington 
DC region during the same time period, patients with 
ﬁ  bromyalgia had no worsening of pain or other somatic 
symptoms following the attacks, compared to just before the 
attack (Williams et al 2003).
Recent reviews regarding the role that “stressors” or 
catastrophic events may have in triggering the development 
of fibromyalgia or related conditions have identified a 
number of factors that may be much more important than 
the intensity of the “stressor” in predicting adverse health 
outcomes. Female gender, worry or expectation of chronicity, 
and inactivity or time off work following the stressor make 
it more likely to trigger the development of pain or other 
somatic symptoms (McLean and Clauw 2004). Naturally 
occurring catastrophic events such as earthquakes, ﬂ  oods, or 
ﬁ  res are much less likely to lead to chronic somatic symptoms 
than similarly stressful events that are “man made” such as 
chemical spills, or war (Clauw et al 2003). Being exposed to a Therapeutics and Clinical Risk Management 2008:4(6) 1335
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multitude of stressors simultaneously, or over a period of time, 
may also be a signiﬁ  cant risk for later somatic symptoms and 
or psychological sequelae. Intensely stressful events can lead 
to permanent changes in the activity of both mouse and human 
stress response systems (Sapolsky 1996; Heim et al 2001).
To complete this vicious circle, these changes in 
baseline function of the stress response that may occur 
following a stressor earlier in life have been shown to pre-
dict which symptom-free individuals without chronic pain 
or other somatic symptoms are more likely to develop these 
somatic symptoms. This has been noted both in population-
based studies and in experiments where healthy young adults 
are deprived of regular sleep or exercise (Glass et al 2004; 
McBeth et al 2007).
This theoretical link between stress, changes in stress axis 
activity, and subsequent susceptibility to develop somatic 
symptoms or syndromes is also supported by studies showing 
that patients with ﬁ  bromyalgia and related conditions may be 
more likely than nonaffected individuals to have experienced 
physical or sexual abuse in childhood (Boisset-Pioro et al 
1995; Drossman 1995; Aaron et al 1997; Alexander et al 
1998). Twin studies have recently supported a link between 
post-traumatic stress disorder (PTSD) and trauma, and CWP 
(Arguelles et al 2006). Just as a lack of or cessation of exercise 
following trauma seems to be associated with a higher 
likelihood of developing pain or other somatic symptoms, 
a recent study of Israeli war veterans with PTSD showed 
that those who exercised regularly were much less likely to 
develop CWP or ﬁ  bromyalgia (Arnson et al 2007).
Augmented pain and sensory processing 
as a hallmark of ﬁ  bromyalgia and related 
syndromes
Once ﬁ  bromyalgia is established, by far the most consistently 
detected objective abnormalities involve pain and sensory 
processing systems. Since ﬁ  bromyalgia is deﬁ  ned in part by 
tenderness, considerable work has been performed exploring 
the potential reason for this phenomenon. The results of 
two decades of psychophysical pressure pain testing in 
ﬁ  bromyalgia have been very instructive.
One of the earliest ﬁ  ndings in this regard was that the 
tenderness in ﬁ  bromyalgia is not conﬁ  ned to tender points, 
but instead extends throughout the entire body (Granges and 
Littlejohn 1993; Wolfe et al 1995). Theoretically, such diffuse 
tenderness could be either primarily due to psychological 
(eg, hypervigilance, where individuals are too attentive to 
their surroundings), or neurobiological factors.
Early studies typically used dolorimetry to assess pressure 
pain threshold, and concluded that tenderness was in large part 
related to psychological factors, because these measures of 
pain threshold were correlated with levels of distress (Wolfe 
et al 1995; Wolfe 1997; Gracely et al 2003). Also, nuances 
such as the rate of increase of stimulus pressure, controlled 
by the operator vs. by the patient, and patient distress have 
been shown to inﬂ  uence pain threshold when it is measured 
in this manner (Jensen et al 1986; Petzke et al 2003b).
To minimize the biases associated with “ascending” (ie, the 
individual knows that the pressure will be predictably increased) 
measures of pressure pain threshold, Petzke and colleagues 
(1999, 2001, 2003a) performed a series of studies using more 
sophisticated paradigms using random delivery of pressures. 
These studies showed that: 1) the random measures of pressure 
pain threshold were not inﬂ  uenced by levels of distress of the 
individual, whereas tender point count and dolorimetry exams 
were, 2) ﬁ  bromyalgia patients were much more sensitive to 
pressure even when these more sophisticated paradigms were 
used, 3) ﬁ  bromyalgia patients were not any more “expectant” 
or “hypervigilant” than controls, and 4) pressure pain thresholds 
at any four points in the body are highly correlated with the 
average tenderness at all 18 tender points and four “control 
points” (the thumbnail and forehead).
Because of this close link between tenderness and 
ﬁ  bromyalgia, this phenomenon has also been well studied as a 
potential relevant outcome in clinical trials of new ﬁ  bromyalgia 
therapies. In a number of longitudinal randomized placebo 
controlled trials fibromyalgia, improvements in clinical 
pain have corresponded with a signiﬁ  cant change in tender 
point counts or tender point index (Farber et al 2000). 
In contrast, other studies did not show a correspondence 
between improvements in clinical pain and tender point 
counts (Scudds et al 1989; Jacobsen et al 1991; Goldenberg 
et al 1996; Arnold et al 2000, 2002; Gowans et al 2001). 
These discrepancies between previous studies could either 
be because these therapies did not improve tenderness, or 
because tender points are not a good measure of tenderness. 
Two recent studies suggest the latter, since when individuals 
with ﬁ  bromyalgia were simultaneously assessed using tender 
point counts, dolorimetry, and random pressure paradigms, the 
random pressure paradigms showed the most responsiveness 
to change (Harris et al 2006; Geisser et al 2007).
Speciﬁ  c mechanisms that may lead 
to a low pain threshold in ﬁ  bromyalgia
There are two different speciﬁ  c pathogenic mechanisms in 
ﬁ  bromyalgia that have been identiﬁ  ed using experimental Therapeutics and Clinical Risk Management 2008:4(6) 1336
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pain testing: 1) an absence or decrease of descending 
analgesic activity, and 2) increased wind-up or temporal 
summation.
Attenuated diffuse noxious inhibitory controls 
(DNIC) in ﬁ  bromyalgia
In healthy humans and laboratory animals, application of 
an intense painful stimulus for two to ﬁ  ve inutes produces 
generalized whole-body analgesia. This analgesic effect, 
termed “diffuse noxious inhibitory controls” (DNIC), has been 
consistently observed to be attenuated or absent in groups of 
ﬁ  bromyalgia patients, compared to healthy controls (Kosek 
and Hansson 1997; Lautenbacher and Rollman 1997; Lefﬂ  er 
et al 2002; Julien et al 2005). Wilder-Smith and Robert-Yap 
(2007) have performed studies suggesting that in IBS there is 
a similar decrease in descending analgesic activity. A point of 
emphasis is that this ﬁ  nding of attenuated DNIC is not found 
in all ﬁ  bromyalgia or IBS patients, but is considerably more 
common in patients than controls.
The DNIC response in humans is believed to be partly 
mediated by descending opioidergic pathways and in part 
by descending serotonergic–noradrenergic pathways. In 
ﬁ  bromyalgia, the accumulating data suggests that oioidergic 
activity is abnormal in ﬁ  bromyalgia, in that levels of cere-
brospinal ﬂ  uid (CSF) enkephalins are roughly twice as high 
in ﬁ  bromyalgia and idiopathic low back pain patients as in 
healthy controls (Baraniuk et al 2004). Moreover, PET data 
show that baseline mu-opioid receptor binding is decreased in 
multiple pain processing regions in the brains of ﬁ  bromyalgia 
patients, consistent with either increased release of endogenous 
mu-opioid ligands in ﬁ  bromyalgia or reduced numbers of 
receptors (Harris et al 2007).
The biochemical and imaging findings suggesting 
altered activity of endogenous opioidergic systems in 
ﬁ  bromyalgia are consistent with the anecdotal experience 
that opioids are generally ineffective analgesics in patients 
with fibromyalgia and related conditions. In contrast, 
studies have shown the opposite for serotonergic and 
noradrenergic activity in ﬁ  bromyalgia. Studies have shown 
that the principal metabolite of norepinephrine, 3-methoxy-
4-hydroxyphenethylene (MPHG), is lower in the CSF of 
ﬁ  bromyalgia patients (Russell et al 1992). Similarly, there 
are data suggesting low serotonin in this syndrome. Patients 
with ﬁ  bromyalgia were shown to have reduced serum levels 
of serotonin and its precursor, L-tryptophan, as well as 
reduced levels of the principal serotonin metabolite, 5-HIAA, 
in their CSF (Russell et al 1992; Yunus et al 1992). Further 
evidence for this mechanism comes from treatment studies, 
where nearly any type of compound that simultaneously 
raises both serotonin and norepinephrine has been shown 
to be efficacious in treating fibromyalgia and related 
conditions (Arnold et al 2000, 2004b; Bennett et al 2003; 
Gendreau et al 2005).
Another important neurotransmitter in pain processing, 
and one that likely is playing some role in ﬁ  bromyalgia, is 
glutamate. Glutamate is a major excitatory neurotransmitter 
within the central nervous system, and cerebrospinal ﬂ  uid 
levels of glutamate are twice as high in fibromyalgia 
patients than controls (Sarchielli et al 2007). Not only 
are these levels elevated, but a recent study using proton 
spectroscopy demonstrated that the glutamate levels in the 
insula in ﬁ  bromyalgia change in response to changes in both 
clinical and experimental pain when patients are treated with 
acupuncture or sham acupuncture (Harris et al 2008).
Thus, a number of lines of evidence point to the fact 
that ﬁ  bromyalgia is a state of heightened pain or sensory 
processing, and that this might occur because of high levels of 
neurotransmitters that increase pain transmission, and/or low 
levels of neurotransmitters that decrease pain transmission.
Abnormalities on functional neuroimaging
Functional neural imaging enables investigators to visualize 
how the brain processes the sensory experience of pain. The 
primary modes of functional imaging that have been used in 
ﬁ  bromyalgia include functional magnetic resonance imag-
ing (fMRI), single photon emission computed tomography 
(SPECT), and positron emission tomography (PET), and 
proton spectroscopy (H-MRS).
Single photon emission computed tomography
Single photon emission computed tomography (SPECT) 
was the ﬁ  rst functional neuroimaging technique to be used 
in ﬁ  bromyalgia. SPECT imaging involves the introduction 
of radioactive compounds into the participant’s blood 
stream, which then decay over time giving a window for 
neural activity assessment. The ﬁ  rst trial using SPECT 
imaging in ﬁ  bromyalgia patients was conducted by Mountz 
and colleagues (1995). Their data from 10 ﬁ  bromyalgia 
patients and seven age- and education-matched healthy 
controls indicated that both the caudate and the thalamus of 
ﬁ  bromyalgia patients had decreased blood ﬂ  ow. The ﬁ  ndings 
by Mountz and colleagues (1995) were largely replicated in 
a second SPECT study by Kwiatek and colleagues (2000). 
In a third SPECT trial, Guedj and colleagues (2007a, 
2007b) reported a study using a more sensitive radioligand 
(99mTc-ECD) in fibromyalgia patients and pain free Therapeutics and Clinical Risk Management 2008:4(6) 1337
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controls. Guedj and colleagues found hyperperfusion in 
ﬁ  bromyalgia patients within the somatosensory cortex and 
hypoperfusion in the anterior and posterior cingulate, the 
amygdala, medial frontal and parahippocampal gyrus, and 
the cerebellum. Finally, if these regional cerebral blood ﬂ  ow 
(rCBF) differences are relevant for ﬁ  bromyalgia pathology, 
one could hypothesize that changes in rCBF should track 
with changes in pain symptoms over time. One longitudinal 
treatment trial used SPECT imaging to assess changes in 
rCBF following administration of amitriptyline within 14 
ﬁ  bromyalgia patients (Adiguzel et al 2004). After three 
months of treatment with amitriptyline, increases in rCBF in 
the bilateral thalamus and the basal ganglia were observed. 
Since the same two regions had been implicated previously, 
these data suggest that amitriptyline may normalize the 
altered blood ﬂ  ow which is associated with reduced pain 
symptoms.
Functional MRI (fMRI)
fMRI is a noninvasive brain imaging technique that relies 
on changes in the relative concentration of oxygenated to 
deoxygenated hemoglobin within the brain. In response to 
neural activity, oxygenated blood ﬂ  ow is increased within 
the local brain area. This causes a decrease in the concen-
tration of deoxygenated hemoglobin. Since deoxygenated 
hemoglobin is paramagnetic, this in turn causes a change 
in the magnetic property of the tissue. Unlike SPECT and 
PET which can measure baseline levels of blood ﬂ  ow, the 
fMRI blood oxygenation level dependent (BOLD) effect 
originates from a difference between experimental condi-
tions and does not assess baseline blood ﬂ  ow. Typically in 
ﬁ  bromyalgia trials involving fMRI, evoked pain sensations 
are compared to “off ” conditions that have either no pain or 
involve an innocuous sensation.
The ﬁ  rst study to use fMRI in ﬁ  bromyalgia patients was 
performed by Gracely and colleagues (2002) In this study 
16 ﬁ  bromyalgia patients and 16 matched controls were 
exposed to painful pressures during the fMRI experiment. 
The authors found increased neural activations (ie, increases 
in the BOLD signal) in patients compared to pain-free 
controls, when stimuli of equal pressure magnitude were 
administered. Regions of increased activity included the 
primary and secondary somatosensory cortex, the insula, 
and the anterior cingulate, all regions commonly observed 
in fMRI studies of healthy normal subjects during painful 
stimuli. Interestingly, when the pain-free controls were 
subjected to pressures that evoked equivalent pain ratings 
in the ﬁ  bromyalgia patients, similar activation patterns 
were observed. These ﬁ  ndings were entirely consistent with 
the “left–shift” in stimulus–response function noted with 
experimental pain testing, and suggest that ﬁ  bromyalgia 
patients experience an increased gain or “volume setting” in 
brain sensory processing systems. In a similar experiment, 
Cook and colleagues used painful heat stimuli during fMRI 
(Cook et al 2004b). Similar to the Gracely and colleagues’ 
ﬁ  ndings, the authors observed signiﬁ  cant increases in the 
pain ratings of patients and augmented pain processing 
within the contralateral insula. fMRI has also proved 
useful in determining how co-morbid psychological factors 
inﬂ  uence pain processing in ﬁ  bromyalgia. For example, a 
recent study by Giesecke and colleagues (2005) explored 
the relationship between depression and enhanced evoked 
pain sensations in 30 patients with ﬁ  bromyalgia. The authors 
found that the anterior insula and amygdala activations 
were correlated with depressive symptoms, consistent with 
these regions being involved with affective or motivational 
aspects of pain processing. However, the degree of neuronal 
activation in areas of the brain thought to be associated 
with the “sensory” processing of pain (ie, where the pain is 
localized and its intensity) were not associated with levels 
of depressive symptoms, or the presence or absence of major 
depression. These data are consistent with a plethora of 
evidence in the pain ﬁ  eld that there are different regions of 
the brain responsible for pain processing devoted to sensory 
intensity versus affective aspects of pain sensation, and 
suggest that the former and latter are largely independent 
of each other. In contrast, this same group showed that 
the presence of catastrophizing, a patient’s negative or 
pessimistic appraisal of their pain, inﬂ  uences both the 
sensory and affective dimensions of pain on fMRI in 
ﬁ  bromyalgia (Gracely et al 2004).
PET has been used in a few studies in ﬁ  bromyalgia. 
In the ﬁ  rst such study, Yunus and colleagues (1997, 2004) 
did not identify any differences in regional cerebral blood 
ﬂ  ow between ﬁ  bromyalgia patients and controls. However, 
Wood and colleagues used PET to show that attenuated 
dopaminergic activity may be playing a role in pain 
transmission in ﬁ  bromyalgia, and Harris and colleagues 
showed evidence of decreased mu opiod receptor availability 
(possibly due to increased release of endogenous mu opioids) 
in ﬁ  bromyalgia (Harris et al 2007).
Treatment
Progress in the understanding of ﬁ  bromyalgia has led to 
more therapeutic options for patients with this condition. 
Investigators are examining the utility of newer medications Therapeutics and Clinical Risk Management 2008:4(6) 1338
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as well as nonpharmacological interventions in controlled 
trials. Clinical based evidence advocates a multi-faceted 
program emphasizing education, certain medications, 
exercise, and cognitive therapy (Goldenberg et al 2004).
Pharmacologic therapy
The majority of ﬁ  bromyalgia clinical trials have involved 
antidepressants of one class or another. Trials studying the 
oldest class of agents, tricyclic antidepressants (TCAs), are 
most abundant, though several recent studies have focused 
on selective serotonin reuptake inhibitors and “atypical 
antidepressants”, a class that includes dual reuptake inhibitors 
and monoamine oxidase inhibitors (MAOIs).
Tricyclic anitdepressants
The most frequently studied pharmacologic therapy for 
ﬁ  bromyalgia is low doses of tricyclic compounds. Most 
TCAs increase the concentrations of serotonin and/or 
norepinephrine (noradrenaline) by directly blocking their 
respective reuptake. The effectiveness of TCAs, particularly 
amitriptyline and cyclobenzaprine, in treating the symptoms 
of pain, poor sleep, and fatigue associated with ﬁ  bromyalgia 
is supported by several randomized, controlled trials (Arnold 
et al 2000). Tolerability is a problem but can be improved 
by beginning at very low doses (eg, 10 mg of amitriptyline), 
giving the dose a few hours before bedtime, and very slowly 
escalating the dose.
Selective serotonin reuptake inhibitors
Because of a better side effect proﬁ  le, newer antidepressants, 
ie, selective serotonin reuptake inhibitors (SSRIs), are 
frequently used in ﬁ  bromyalgia. The SSRIs ﬂ  uoxetine, 
citalopram, and paroxetine have each been evaluated in 
randomized, placebo controlled trials (Norregaard et al 
1995; Anderberg et al 2000; Capaci and Hepguler 2002; 
Goldenberg et al 2004). In general, the results of studies 
of SSRIs in ﬁ  bromyalgia have paralleled the experience 
in other pain conditions. The newer “highly selective” 
serotonin reuptake inhibitors such as citalopram, seem to 
be less efﬁ  cacious than the older SSRIs, which have some 
noradrenergic activity at higher doses (Fishbain 2000).
Since TCAs, and high doses of certain “SSRIs” such 
as ﬂ  uoxetine and sertraline, that have the most balanced 
re-uptake inhibition are the most effective analgesics, 
many have concluded that dual receptor inhibitors such as 
serotonin-NE and NE-serotonin reuptake inhibitors (SNRIs 
and NSRIs) may be of more beneﬁ  t than pure serotonergic 
drugs (Fishbain 2000). These drugs are pharmacologically 
similar to some TCAs in their ability to inhibit the reuptake 
of both serotonin and NE, but differ from TCAs in being 
generally devoid of signiﬁ  cant activity at other receptor 
systems. This selectivity results in diminished side effects and 
enhanced tolerability. The ﬁ  rst available SNRI, venlafaxine, 
has data to support its use in the management of neuropathic 
pain, and retrospective trial data demonstrate that this 
compound is also effective in the prophylaxis of migraine 
and tension headaches (Adelman et al 2000). Two studies in 
ﬁ  bromyalgia have had conﬂ  icting results, with the one using 
a higher dose showing efﬁ  cacy (Goldenberg et al 2004).
Milnacipran and duloxetine
Two new SNRIs, milnacipran and duloxetine, have undergone 
recent multicenter trials and were shown to be effective in 
a number of outcome variables (Arnold et al 2004b; Vitton 
et al 2004). These newer drugs have promise for reducing 
pain symptoms in ﬁ  bromyalgia. In the Vitton and colleagues 
(2004) study evaluating milnacipran, statistically signiﬁ  cant 
differences were noted in overall improvement, physical 
functioning, level of fatigue and degree of reported physical 
impairment. In the Arnold and colleagues (2004b) trial of 
duloxetine compared to placebo, participants treated with 
duloxetine had decreased self-reported pain and stiffness, 
and a reduced number of tender points. In both trials, beneﬁ  ts 
were shown to be independent of the drug effect on mood, 
thus suggesting that the analgesic and other positive effects 
of milnacipran and duloxetine in ﬁ  bromyalgia are not simply 
due to their antidepressant effects. Also both studies found 
these drugs to be generally well tolerated, with side effects 
commonly seen with this class of drugs such as nausea and 
palpitations, as well as mild changes in pulse and blood 
pressure in some patients.
Within the Vitton and colleagues (2004) study, the 
analgesic response seen with milnacipran was rapid and 
sustained. However, it is clear that this drug is not simply 
acting as an analgesic, because there were parallel changes 
seen in other domains such as depression, fatigue, and 
cognition over the course of the study. These improvements 
in fatigue and cognition may be due to the fact that 
milnacipran has proportionally greater noradrenergic than 
serotinergic re-uptake effects, when compared with other 
dual re-uptake inhibitors.
It is unlikely that the beneﬁ  cial effects of milnacipran are 
due to its antidepressant properties (Briley et al 1996). This trial 
excluded patients with major depression, and in spite of this 
improvement efﬁ  cacy was seen across a number of domains. 
Other studies of dual re-uptake inhibitors such as tricyclics Therapeutics and Clinical Risk Management 2008:4(6) 1339
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and duloxetine have similarly shown that the analgesic efﬁ  cacy 
of these compounds across a variety of pain conditions is 
similar in depressed and nondepressed individuals (Arnold 
2007; Fishbain 2000). These ﬁ  ndings are also consistent 
with current theories of pain processing which suggest that 
the sensory processing of pain (ie, where it is located and 
how much it hurts) occurs in different brain regions than the 
affective and cognitive processing of pain (ie, the emotional 
valence and cognitive appraisal of pain) (Derbyshire 2000). 
In fact, functional neuroimaging studies in ﬁ  bromyalgia have 
identiﬁ  ed augmented central pain processing in the regions 
of the brain associated with the sensory and affective 
processing of pain, and have demonstrated that the magnitude 
of neuronal hyperactivity seen with painful stimuli in the 
sensory regions (eg, the primary and secondary somatosensory 
cortices) is independent of whether the ﬁ  bromyalgia patient 
is depressed or not (Gracely et al 2002; Cook et al 2004a; 
Giesecke, et al 2005).
The fact that a drug that inhibits the reuptake of 
serontonin and norepinephrine is efﬁ  cacious in ﬁ  bromyalgia 
is not surprising. There are abundant data suggesting that 
at least a subset of ﬁ  bromyalgia patients has a deﬁ  ciency in 
serotinergic and noradrenergic activity that is responsible 
for their pain, tenderness, and other symptoms. Studies 
have shown that the principal metabolite of norepinephrine, 
3-methoxy-4-hydroxyphenethylene (MPHG), is lower 
in the CSF of ﬁ  bromyalgia patients (Russell et al 1992). 
Similarly, there are data suggesting low serotonin in this 
syndrome. Patients with ﬁ  bromyalgia have been shown to 
have reduced serum levels of serotonin and its precursor, 
L-tryptophan, as well as reduced levels of the principal 
serotonin metabolite, 5-HIAA, in their CSF (Russell 
et al 1992; Yunus et al 1992).
The prevailing theory is that this decreased serotinergic 
and noradrenergic activity leads to a decrease in activity 
via descending analgesic pathways, which in turn leads 
to the pain as well as diffuse hyperalgesia and allodynia 
seen in ﬁ  bromyalgia and a number of related conditions. 
As mentioned above, in healthy humans and laboratory 
animals, application of an intense painful stimulus for two 
to ﬁ  ve minutes produces generalized whole-body analgesia, 
termed “diffuse noxious inhibitory controls” (DNIC). 
This is believed to be partly mediated by descending 
opioidergic pathways and in part by descending serotonergic-
noradrenergic pathways. DNIC has been consistently 
observed to be attenuated or absent in groups of ﬁ  bromyalgia 
patients, compared to healthy controls (Kosek and Hansson 
1997; Lautenbacher and Rollman 1997; Lefﬂ  er et al 2002; 
Julien et al 2005). In ﬁ  bromyalgia, the accumulating data 
suggests that opioidergic activity is abnormal, in that levels 
of cerebrospinal ﬂ  uid (CSF) enkephalins are roughly twice 
as high in ﬁ  bromyalgia and idiopathic low back pain patients 
as in healthy controls (Baraniuk et al 2004). Moreover, 
positron emission tomography data show that baseline 
mu-opioid receptor binding is decreased in multiple pain 
processing regions in the brains of ﬁ  bromyalgia patients, 
consistent with the hypothesis that there is increased release 
of endogenous mu-opioid ligands or reduced receptor number 
in ﬁ  bromyalgia leading to high baseline occupancy of the 
receptors (Harris et al 2007). Thus, although it has not been 
deﬁ  nitively proven that compounds that raise both serotonin 
and norepinephrine act as analgesics by restoring descending 
analgesic activity in ﬁ  bromyalgia and a number of other 
chronic pain states, there is compelling evidence that this is 
likely to be the case.
In addition to leading to improvements in a number of 
symptoms, administration of milnacipran was also associated 
with improvements in functional status (Vitton et al 2004). 
This is important, since the functional status of ﬁ  bromyalgia 
patients is very impaired, compared to healthy controls 
(Kop et al 2005). It is likely that much greater improvements 
in functional status would be noted if patients were given 
non-pharmacological therapies such as exercise and cognitive 
behavioral therapy as well as milnacipran or other drugs, as 
these nondrug therapies typically have more robust effects 
on function (O’Malley et al 2000).
Although milnacipran was generally well tolerated, 
approximately twice as many individuals in the active 
treatment group withdrew from the study because of adverse 
effects as those in the placebo-treated group (Vitton et al 
2004). The most common side effects seen with the drug 
were nausea, constipation, palpitations, and ﬂ  ushing. These 
side effects are typically noted with this class of drugs, and 
these symptoms often resolve within days to weeks. These 
side effects also can be reduced if this class of drug is taken 
with food and the dose is escalated slowly. There were also 
notable effects on both pulse and blood pressure seen in 
a small percentage of individuals receiving milnacipran, 
presumably due to the noradrenergic effects, so individuals 
should be monitored for these side effects.
In conclusion, milnacipran dosed BID at 100 or 200 mg per 
day led to global improvements in ﬁ  bromyalgia, characterized 
by relief of pain, fatigue, and other symptoms (Vitton et al 
2004). Further studies will help clarify the precise role 
of this and other compounds in treating ﬁ  bromyalgia in 
clinical practice. Like many drugs used for many diseases, Therapeutics and Clinical Risk Management 2008:4(6) 1340
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this compound clearly does not work in all individuals with 
ﬁ  bromyalgia, which should not be surprising given that 
emerging evidence suggests that this is a polygenic illness 
with many root causes (Arnold et al 2004a; Buskila et al 
2007). It may often be necessary to use this compound in 
combination with other drugs with different mechanisms 
of action, and with nondrug therapies such as exercise and 
cognitive behavioral therapy, to achieve a more complete 
response in most ﬁ  bromyalgia patients.
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